Abstract is: Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in Europe in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines. The World Health Organization (WHO) recommends universal vaccination in areas where the disease is moderately common. Where the disease is very common, widespread vaccination is not recommended as all people typically develop immunity through infection during childhood. The Centers for Disease Control and Prevention (CDC) recommends vaccinating: * All children aged 12–23 months * Unvaccinated children and adolescents aged 2–18 years * International travelers * Men who have sex with men * People who use injection or non-injection drugs * People who have occupational risk for infection * People who anticipate close contact with an international adoptee * People experiencing homelessness * People with HIV * People with chronic liver disease * Any person wishing to obtain immunity In addition, a person who has not previously received hepatitis A vaccine and who has direct contact with someone with hepatitis A should get hepatitis A vaccine within two weeks after exposure. Severe side effects are very rare. Pain at the site of injection occurs in about 15% of children and half of adults. Most hepatitis A vaccines contain inactivated virus while a few contain weakened virus. The ones with weakened virus are not recommended during pregnancy or in those with poor immune function. A few formulations combine hepatitis A with either hepatitis B or typhoid vaccine. Soreness or redness where the shot is given, fever, headache, tiredness, or loss of appetite can happen after hepatitis A vaccine. As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.
| vaccine type | Q105967696 |
| essential medicine | Q35456 |
| viral hepatitis vaccines | Q58624032 |
| P267 | ATC code | J07BC02 |
| P646 | Freebase ID | /m/02z0_zb |
| P3827 | JSTOR topic ID (archived) | hepatitis-a-vaccines |
| P10245 | MedlinePlus drug identifier | a695003 |
| P486 | MeSH descriptor ID | D022362 |
| P672 | MeSH tree code | D20.215.894.899.955.395 |
| P6366 | Microsoft Academic ID | 2780799908 |
| P10283 | OpenAlex ID | C2780799908 |
| P3417 | Quora topic ID | Hepatitis-A-Vaccine |
| P2892 | UMLS CUI | C0170300 |
| P11143 | WikiProjectMed ID | Hepatitis A vaccine |
| P6363 | WordLift URL | http://data.medicalrecords.com/medicalrecords/healthwise/hepatitis_a_vaccine__what_you_need_to_know |
| P1716 | brand | Twinrix | Q17066597 |
| P636 | route of administration | intramuscular injection | Q432083 |
| P1924 | vaccine for | hepatitis A | Q157661 |
| Q57111592 | A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children |
| Q77524597 | A dose response study of hepatitis A vaccine in healthy adults who are > or = 30 years old and weigh > or = 77 kg |
| Q47245555 | A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults |
| Q45737449 | A prevalence study of hepatitis A virus infection in a migrant community: Is hepatitis A vaccine indicated? |
| Q74305688 | A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim |
| Q37561214 | A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children |
| Q40767575 | A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection |
| Q45886774 | A study to assess the immunogenicity, reactogenicity and safety of hepatitis A vaccine administered subcutaneously to patients with congenital coagulation disorders |
| Q72068283 | A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine |
| Q73372381 | AAP develops guidelines for hepatitis A vaccine and immune globulin in children. American Academy of Pediatrics |
| Q81373856 | Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine |
| Q72592858 | Administration of hepatitis A vaccine to a military population by needle and jet injector and with hepatitis B vaccine |
| Q72955529 | Adult use of hepatitis A vaccine in developed countries |
| Q95618546 | Afebrile convulsion: a rare complication of inactivated hepatitis A vaccine in childhood |
| Q89956542 | Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice |
| Q38951477 | An Advisory Committee Statement (ACS). Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on hepatitis A vaccines for travellers |
| Q77164270 | An Advisory Committee Statement (ACS). Update on hepatitis A vaccine (Avaxim, Aventis Pasteur) |
| Q47566972 | An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study. |
| Q40581199 | An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. |
| Q80513915 | An open study of inactivated hepatitis A vaccine (VAQTA) in Taiwanese healthy adult volunteers: safety, tolerability, and immunogenicity |
| Q74100892 | An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity |
| Q81463722 | Another success for hepatitis A vaccine |
| Q50992687 | Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. |
| Q74430118 | Antibody responses to Hepatitis A vaccine in healthy adults |
| Q47426586 | Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®) |
| Q44801558 | Assessment of inactivation of hepatitis A vaccine by compound PCR |
| Q64386663 | Autoimmunity and hepatitis A vaccine in children |
| Q34159572 | Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). |
| Q91835651 | Can Hepatitis A Vaccine Provide Protection Against COVID-19? |
| Q80961085 | Cell mediated and antibody immune response to inactivated hepatitis A vaccine |
| Q45850581 | Characteristics of inactivated hepatitis A vaccine prepared from virus propagated in heteroploid continuous monkey cell line |
| Q67508514 | Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate |
| Q35237369 | Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings |
| Q44601269 | Clinical development of a new inactivated hepatitis A vaccine |
| Q91920369 | Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric |
| Q68480553 | Clinical trial of inactivated hepatitis A vaccine |
| Q35821266 | Clinical trial with inactivated hepatitis A vaccine and recommendations for its use |
| Q40491455 | Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years |
| Q45353389 | Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. |
| Q36805483 | Comparative study of the immunogenicity of the inactivated hepatitis A vaccine Hep-A-in-vac from experimental and clinical data |
| Q45343889 | Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose |
| Q41235777 | Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study |
| Q41118643 | Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose |
| Q37375908 | Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study |
| Q42267455 | Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China |
| Q64257061 | Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study |
| Q77757768 | Comparison of the reactogenicity and immunogenicity of two different dose levels of hepatitis A vaccine in healthy children and adolescents |
| Q40681526 | Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study |
| Q50849729 | Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM). |
| Q80847829 | Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial |
| Q37530087 | Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children |
| Q44982052 | Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults |
| Q36868540 | Construction of gene library of attenuated liver hepatitis A vaccine (H2 strain) |
| Q73006038 | Control of a community hepatitis A outbreak using hepatitis A vaccine |
| Q57106556 | Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine |
| Q93717798 | Correction: Clinical trials with inactivated hepatitis A vaccine and recommendations for its use |
| Q57189087 | Corrigendum to " An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study" [Trav. Med. Infect. Dis. 21, January-February 2018, 43-50] |
| Q80555720 | Cost of hepatitis A vaccine: $70. Mounting your own antibody response to hepatitis A before your overseas holiday: priceless |
| Q34726910 | Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies |
| Q47685158 | Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection |
| Q45255598 | Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. |
| Q36378571 | Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. |
| Q67861575 | Development of live attenuated hepatitis A vaccine (H2-strain) |
| Q41176133 | Development of live, attenuated hepatitis A vaccine (H2-strain). |
| Q40752125 | Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. |
| Q37725154 | Development, production, and postmarketing surveillance of hepatitis A vaccines in China |
| Q40623581 | Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines? |
| Q73688090 | Don't forget the hepatitis A vaccine |
| Q74521560 | Don't forget the hepatitis A vaccine |
| Q74106291 | Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster |
| Q73653658 | Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine |
| Q47997899 | Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants |
| Q77800215 | Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA |
| Q56534948 | Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placebo‐Controlled Trial |
| Q72592851 | Efficacy of an inactivated hepatitis A vaccine in pre- and postexposure conditions in marmosets |
| Q39499728 | Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial |
| Q40391929 | Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis |
| Q50758077 | Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. |
| Q80954740 | Efficient postexposure prophylaxis by hepatitis A vaccine |
| Q36798174 | Emerging need for vaccination against hepatitis A virus in patients with chronic liver disease in Korea |
| Q46160505 | Establishment of a biological reference preparation for hepatitis A vaccine (inactivated, non-adsorbed). |
| Q91070576 | Establishment of detection antibodies BRRs batch 5 for in vitro potency assay of hepatitis A vaccines by ELISA |
| Q48874429 | Establishment of hepatitis A vaccine (inactivated, non-adsorbed) BRP batches 2 and 3. |
| Q78561221 | Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2 |
| Q37233646 | Evaluation of hepatitis A vaccine in post-exposure prophylaxis, The Netherlands, 2004-2012. |
| Q40462960 | Evaluation of immunogenicity and tolerability of a live attenuated hepatitis a vaccine in Indian children. |
| Q34725773 | Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more |
| Q78100563 | Evaluation of the purity of a purified, inactivated hepatitis A vaccine (VAQTA) |
| Q40248685 | Evaluation on the effect of immunization and safety of live attenuated and inactivated hepatitis A vaccine in China |
| Q41558010 | Evaluation on the hepatitis A vaccine in preventing hepatitis A infection in Tianjin, from 2000 to 2011 |
| Q27023186 | Evidence-to-policy gap on hepatitis A vaccine adoption in 6 countries: Literature vs. policymakers' beliefs |
| Q56945534 | Factors influencing a communitywide campaign to administer hepatitis A vaccine to men who have sex with men |
| Q87543427 | Field effectiveness of hepatitis A vaccine and uptake of post exposure prophylaxis following a change to the Australian guidelines |
| Q56995465 | Field efficacy trial of inactivated hepatitis A vaccine among children in Thailand (an extended abstract) |
| Q67508521 | Field evaluation of a hepatitis A vaccine in a Norwegian contingent to the United Nations Interim Force in Lebanon |
| Q64132195 | Field performance of VAQTA (inactivated, purified hepatitis a vaccine) in Chinese children in Jiangsu |
| Q42185655 | Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina |
| Q71963852 | From the Centers for Disease Control and Prevention. Licensure of inactivated hepatitis A vaccine and recommendations for international travelers' use |
| Q45935280 | Further evaluation of a live hepatitis A vaccine in marmosets. |
| Q73598391 | Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans |
| Q71932276 | Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults |
| Q37449617 | Hepatitis A Vaccine Response in Human Immunodeficiency Virus-infected Patients: The Interchangeability of Single Dose versus Double: A Prospective Look |
| Q92555793 | Hepatitis A Vaccine and International Travel |
| Q74804588 | Hepatitis A after a single dose of an inactivated hepatitis A vaccine |
| Q73502937 | Hepatitis A vaccine administration: comparison between jet-injector and needle injection |
| Q45191914 | Hepatitis A vaccine and travel departure |
| Q36804325 | Hepatitis A vaccine associated with autoimmune hepatitis |
| Q67241740 | Hepatitis A vaccine could follow 'B' immunization |
| Q77935161 | Hepatitis A vaccine development: a personal perspective |
| Q57080503 | Hepatitis A vaccine failure |
| Q44744165 | Hepatitis A vaccine failure: how to treat the threat |
| Q38881993 | Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study |
| Q57515368 | Hepatitis A vaccine for secondary hepatitis A infection |
| Q78106702 | Hepatitis A vaccine for secondary hepatitis A infection |
| Q93925003 | Hepatitis A vaccine for secondary hepatitis A infection |
| Q93925007 | Hepatitis A vaccine for secondary hepatitis A infection |
| Q46129762 | Hepatitis A vaccine for sewage workers. |
| Q46129809 | Hepatitis A vaccine for sewage workers: Authors' reply. |
| Q71973655 | Hepatitis A vaccine gains marketing approval |
| Q57100983 | Hepatitis A vaccine immune response 22 years after vaccination |
| Q58539434 | Hepatitis A vaccine immune response 22 years after vaccination |
| Q90109542 | Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis |
| Q44992581 | Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens |
| Q77325483 | Hepatitis A vaccine in pediatric patients affected by metabolic liver diseases |
| Q33991271 | Hepatitis A vaccine in the last-minute traveler |
| Q95823047 | Hepatitis A vaccine interchangeability |
| Q47864634 | Hepatitis A vaccine is not required in adult patients with chronic liver disease in Saudi Arabia. |
| Q44090256 | Hepatitis A vaccine recommendations |
| Q38070623 | Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable? |
| Q44531135 | Hepatitis A vaccine responses in HIV-positive persons with haemophilia |
| Q72617888 | Hepatitis A vaccine set for 2-year-olds to adults |
| Q36552925 | Hepatitis A vaccine should receive priority in National Immunization Schedule in India |
| Q43523893 | Hepatitis A vaccine shows promise |
| Q45182852 | Hepatitis A vaccine strategies and relevance in the present scenario. |
| Q92185377 | Hepatitis A vaccine uptake among men who have sex with men from a time-limited vaccination programme in Melbourne in 2018 |
| Q46646899 | Hepatitis A vaccine uptake in San Diego County: Hispanic children are better immunized |
| Q47870190 | Hepatitis A vaccine versus immune globulin for postexposure prophylaxis |
| Q80594678 | Hepatitis A vaccine versus immune globulin for postexposure prophylaxis |
| Q44088810 | Hepatitis A vaccine versus immunoglobulin for post-exposure prophylaxis. |
| Q46000323 | Hepatitis A vaccine: current indications. |
| Q77790558 | Hepatitis A vaccine: evidence of efficacy after exposure |
| Q53300664 | Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. |
| Q52003474 | Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. |
| Q33878447 | Hepatitis A vaccine: is it being used to best advantage? |
| Q73671207 | Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination |
| Q41716264 | Hepatitis A vaccine: ready for prime time |
| Q43690627 | Hepatitis A vaccine: time for universal immunization |
| Q72647782 | Hepatitis A vaccine: which dose is best? |
| Q36650880 | Hepatitis A vaccines and the elderly |
| Q68080618 | Hepatitis A vaccines considered for licensing |
| Q40142583 | Hepatitis A vaccines: How will we use them? |
| Q41067732 | Hepatitis A vaccines: past, present, and future. |
| Q36066059 | Hepatitis A vaccines: the growing case for universal immunisation of children |
| Q26799782 | Hepatitis B and A vaccination in HIV-infected adults: A review |
| Q73844513 | Hepatitis a vaccine in liver transplant recipients |
| Q47275466 | Hepatitis and hepatitis A vaccine: a glimpse of history |
| Q71764054 | High immunogenicity and good tolerability of a new hepatitis A vaccine candidate |
| Q54216957 | High prevalence of anti-hepatitis A IgG in a cohort of UK HIV-negative men who have sex with men: implications for local hepatitis A vaccine policy. |
| Q68436275 | IHF proposes hepatitis A vaccine immunogenicity and efficacy trials |
| Q43793424 | IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization |
| Q77553262 | Immune Response to Hepatitis A Vaccine Combined or Given Simultaneously with Typhoid Fever Vaccine |
| Q44404749 | Immune response to a single dose of a novel kind of hepatitis A vaccine following splenectomy |
| Q92486155 | Immune response to hepatitis A vaccine in patients with HIV |
| Q40145127 | Immune response to one booster dose of inactivated hepatitis A vaccine in college students |
| Q72592861 | Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year |
| Q73865844 | Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules |
| Q73527365 | Immunogenecity of hepatitis A vaccine in children below 2 years of age |
| Q84984314 | Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease |
| Q61771590 | Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine Given with Measles-Mumps-Rubella Vaccine to 12-13 Month Old Turkish Children |
| Q44048281 | Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial |
| Q57109807 | Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children |
| Q38939235 | Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study |
| Q44095168 | Immunogenicity and long-term persistence of anti-HAV in groups with different attenuated and inactived hepatitis A vaccine dosage |
| Q40624353 | Immunogenicity and reactogenicity of an inactivated hepatitis A vaccine in Indian adults |
| Q53913618 | Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults. |
| Q71748623 | Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study |
| Q78684620 | Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study |
| Q71764067 | Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route |
| Q34291194 | Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India |
| Q64933752 | Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. |
| Q57002601 | Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children |
| Q45051660 | Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile |
| Q50114310 | Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly |
| Q80641030 | Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients |
| Q44887403 | Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. |
| Q71075331 | Immunogenicity and safety of an inactivated hepatitis A vaccine amongst Singaporeans |
| Q44025624 | Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children |
| Q71923414 | Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men |
| Q42636837 | Immunogenicity and safety of an inactivated hepatitis A vaccine in children with Down syndrome |
| Q83866762 | Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age |
| Q84206030 | Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age |
| Q81415124 | Immunogenicity and safety of an inactivated hepatitis a vaccine administered concomitantly with a pneumococcal conjugate vaccine in healthy children 15 months of age |
| Q44518836 | Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease |
| Q52975848 | Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. |
| Q83264812 | Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study |
| Q40117399 | Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study |
| Q81036318 | Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial |
| Q40542156 | Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: comparison of three vaccination schedules |
| Q91415155 | Immunogenicity and side-effects of the inactivated hepatitis A vaccine in periodic fever, aphthous stomatitis, pharyngitis, and adenitis patients |
| Q85064985 | Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years |
| Q80390695 | Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children |
| Q69369583 | Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers |
| Q47613191 | Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries |
| Q71471688 | Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response |
| Q72042129 | Immunogenicity of an inactivated hepatitis A vaccine after exposure at 37 degrees C for 1 week |
| Q64135080 | Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults |
| Q44022707 | Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops |
| Q71015534 | Immunogenicity of an inactivated hepatitis A vaccine in healthy children: two years' follow-up |
| Q44217248 | Immunogenicity of an inactivated hepatitis A vaccine in infants and young children |
| Q38898919 | Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine |
| Q84132789 | Immunogenicity of hepatitis A vaccine in children with celiac disease |
| Q44194285 | Immunogenicity of hepatitis A vaccine in decompensated liver disease |
| Q79300897 | Immunogenicity of hepatitis a vaccine in children with cancer |
| Q70634969 | Immunogenicity of inactivated hepatitis A vaccine in children |
| Q47349877 | Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease |
| Q82949694 | Immunogenicity of single dose live attenuated hepatitis a vaccine |
| Q96338934 | Immunogenicity of the hepatitis A vaccine 20 years after infant immunization |
| Q50969746 | Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. |
| Q89628673 | Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction |
| Q94587498 | Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study |
| Q81566421 | Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children |
| Q67871144 | Immunological effects of live attenuated hepatitis A vaccine |
| Q43788316 | Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study |
| Q73816644 | Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies |
| Q45762155 | Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin |
| Q36175752 | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review |
| Q73584547 | In vitro potency assay for hepatitis A vaccines: development of a unique economical test |
| Q67902905 | Inactivated hepatitis A vaccine |
| Q73067768 | Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose |
| Q73204679 | Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection |
| Q43939694 | Inactivated hepatitis A vaccine in childhood: implications for disease control |
| Q70917161 | Inactivated hepatitis A vaccine in healthy Chinese adults |
| Q44493327 | Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals |
| Q72592854 | Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals |
| Q44326184 | Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees |
| Q35195906 | Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. |
| Q39591635 | Inactivated hepatitis A vaccine: long-term antibody persistence |
| Q72646916 | Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence |
| Q72365603 | Inactivated hepatitis A vaccines |
| Q72665776 | Inactivated virosome hepatitis A vaccine |
| Q72677518 | Inactivated virosome hepatitis A vaccine |
| Q72073848 | Inadequate response to intradermal hepatitis A vaccine |
| Q81488434 | Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine |
| Q43823874 | Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children |
| Q44642735 | Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey |
| Q40665395 | Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults |
| Q79760935 | Is it time to introduce hepatitis A vaccine into routine childhood immunisations? |
| Q80644066 | Is the hepatitis A vaccine an alternative for postexposure prophylaxis? |
| Q67508503 | Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine |
| Q53374190 | Licensure of inactivated hepatitis A vaccine and recommendations for use among international travelers. |
| Q26866356 | Live attenuated hepatitis A vaccines developed in China |
| Q35887102 | Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children. |
| Q97867943 | Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children |
| Q40792404 | Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age. |
| Q35696915 | Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions |
| Q51053523 | Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. |
| Q83094282 | Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children |
| Q80205529 | Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up |
| Q59349549 | Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study |
| Q38970499 | Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients |
| Q86200153 | Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children |
| Q102209626 | Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study |
| Q51123569 | Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program. |
| Q100457670 | Low Immune Response Rate of HIV-Infected Patients to a Single Injection of Hepatitis A Vaccine |
| Q98512985 | Modeling the Long-term Antibody Response and Duration of Immune Protection Induced by an Inactivated, Preservative-free Hepatitis A Vaccine (Healive) in Children |
| Q79252966 | Neurological adverse event after administration of the hepatitis A vaccine |
| Q44695973 | New findings in live, attenuated hepatitis A vaccine development |
| Q41177957 | New hepatitis A vaccines and their role in prevention |
| Q51817463 | Outcomes, Approaches, and Challenges to Developing and Passing a Countywide Mandatory Vaccination Policy: St. Louis County's Experience with Hepatitis A Vaccine for Food Service Personnel. |
| Q46269132 | Parental Knowledge, Attitudes, and Practices Associated With Not Receiving Hepatitis A Vaccine in a Demonstration Project in Butte County, California |
| Q72600703 | Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients |
| Q73312616 | Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study |
| Q30151470 | Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska |
| Q44787640 | Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up |
| Q37356170 | Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina |
| Q44363467 | Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. |
| Q81224748 | Physician beliefs and practices regarding the use of hepatitis A vaccine |
| Q67508518 | Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile |
| Q40806748 | Predictors of hepatitis A vaccine coverage among university students in Korea |
| Q71850446 | Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. American Academy of Pediatrics Committee on Infectious Diseases |
| Q35641793 | Prevention of hepatitis A with the hepatitis A vaccine |
| Q44024214 | Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans |
| Q86200142 | Programmatic perspective of single dose hepatitis A vaccine administered in childhood |
| Q72930882 | Progress toward a live, attenuated human hepatitis A vaccine |
| Q68486739 | Prospects for the introduction of hepatitis A vaccine into public health use |
| Q37257799 | Protective effect of inactivated hepatitis A vaccine against the outbreak of hepatitis A in an open rural community |
| Q73294580 | Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines |
| Q74841414 | Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines |
| Q79349610 | Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers |
| Q67525446 | Reactogenicity and immunogenicity of inactivated hepatitis A vaccines |
| Q67508512 | Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine |
| Q39056372 | Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers |
| Q36461602 | Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents |
| Q38036702 | Recent advances in hepatitis A vaccine development |
| Q94703962 | Recent advances with a virosomal hepatitis A vaccine |
| Q59201039 | Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees |
| Q42763977 | Recommendations for use of hepatitis A vaccine |
| Q45951036 | Recommendations for use of hepatitis A vaccine: Authors' reply. |
| Q64243904 | Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness |
| Q45859038 | Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization |
| Q84801333 | Reduction in the prevalence of antibody to hepatitis A virus among young Saudi adults: implications for hepatitis A vaccine |
| Q77553160 | Response to Hepatitis A Vaccine in Children after a Single Dose with a Booster Administration 6 Months Later |
| Q59177258 | Response to hepatitis A vaccine in HIV patients in the HAART era |
| Q51822029 | Response to hepatitis A vaccine in HIV-positive patients. |
| Q85003398 | Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab |
| Q36849799 | Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive® |
| Q91531657 | Review of long term immunogenicity and tolerability of live hepatitis A vaccine |
| Q45726048 | Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial |
| Q77553108 | Safety and Immunogenicity of a High-Potency Inactivated Hepatitis A Vaccine |
| Q33866502 | Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. |
| Q40649425 | Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine |
| Q40608886 | Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children |
| Q46052252 | Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects |
| Q45235063 | Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old. |
| Q72592863 | Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children |
| Q41469662 | Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule |
| Q45012673 | Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. |
| Q44879256 | Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers |
| Q70464519 | Safety and immunogenicity of hepatitis A vaccine in healthy children |
| Q74601717 | Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme |
| Q42673894 | Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease |
| Q73406638 | Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease |
| Q43350376 | Safety and immunogenicity of lyophilized, live attenuated hepatitis A vaccine in non-human primate model |
| Q40622636 | Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia |
| Q58595656 | Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study |
| Q40630612 | Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children |
| Q57003498 | Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais |
| Q44351131 | Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. |
| Q72417827 | Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin |
| Q64136153 | Serological approaches to distinguish immune response to hepatitis A vaccine and natural infection |
| Q77600318 | Seroprevalence of hepatitis A in children--implications for hepatitis A vaccine |
| Q41933109 | Seven-year follow-up of the immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina |
| Q44579161 | Should Hepatitis A Vaccine Coverage be Expanded? |
| Q93869536 | Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity |
| Q38116263 | Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations |
| Q92585752 | Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina |
| Q52850386 | Studies in Chimpanzees of Live, Attenuated Hepatitis A Vaccine Candidates |
| Q35066156 | Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years |
| Q74117375 | Supplementary statement on hepatitis A vaccine (ACS-4). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI) |
| Q84055852 | Surveying adverse event rates: lessons from a virosomal hepatitis A vaccine |
| Q72295938 | Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines |
| Q40616176 | The coverage of hepatitis A vaccine among 2-29 year olds and the reporting incidence of hepatitis A in China, 2014 |
| Q47305437 | The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults |
| Q44444696 | The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up |
| Q35040478 | The effect of policy changes on hepatitis A vaccine uptake in Arizona children, 1995-2008. |
| Q35126721 | The effectiveness and safety of hepatitis A vaccine: a systematic review |
| Q36389001 | The first case of Kawasaki disease in a 20-month old baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: A case report |
| Q72417830 | The immune response to different doses of inactivated hepatitis A vaccine |
| Q49343098 | The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. |
| Q89656523 | The impact of universal live attenuated hepatitis A vaccines in Henan, China, 2005-2018 |
| Q74618519 | The need for immunoglobulin for travelers who receive hepatitis A vaccine |
| Q74246526 | The pros and cons of using hepatitis A vaccine to control outbreaks |
| Q78041224 | The requirement for hepatitis A vaccine in Gurkha soldiers |
| Q45913752 | The response to hepatitis a vaccine in children with JIA on immunosuppresive treatment. |
| Q50847511 | The response to the inactivated Hepatitis A vaccine in children with autoinflammatory diseases: a prospective observational controlled study. |
| Q72961866 | The success of hepatitis A vaccine |
| Q43501387 | The trial preparation of attenuated live hepatitis A vaccine |
| Q73389099 | The use of hepatitis A vaccine in Italy—evidence-based recommendations from an expert panel |
| Q41001700 | The utilisation of hepatitis A vaccine 1992-1994. |
| Q39591643 | Thermostability of an inactivated hepatitis A vaccine stored at 37 degrees C for one week |
| Q71971486 | Two year old hepatitis A vaccine is as good as new |
| Q32060336 | Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). |
| Q58077212 | Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel |
| Q53187217 | Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. |
| Q39408758 | Uptake and attitudes regarding hepatitis A vaccine among childcare centre staff, administrators, and parents |
| Q64137970 | Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use |
| Q40840050 | Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. |
| Q91352668 | Vaccination coverage and its determinants of live attenuated hepatitis A vaccine among children aged 24-59 months in 20 rural counties of 10 provinces of China in 2016 |
| Q56924880 | Vaccines. Response to hepatitis A vaccine weak in some PHAs |
| Q33720842 | Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment |
| Q84938465 | Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration |
| Q73686998 | WHO position paper on hepatitis A vaccines |
| Q84826379 | WHO position paper on hepatitis A vaccines – June 2012 |
| Q85407834 | WHO position paper on hepatitis A vaccines: June 2012-recommendations |
| Q53182167 | Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release? |
| Q73193877 | [A comparative study on safety and immunogenicity of an inactivated hepatitis A vaccine in HBsAg carriers and healthy children] |
| Q77629631 | [A field evaluation of the epidemiological efficacy of an attenuated live hepatitis A vaccine (H2 strain)] |
| Q84342606 | [Analysis on coverage of hepatitis A vaccine among pre-school children in Shandong province] |
| Q64129990 | [Analysis on epidemiological and serum effect after vaccination of hepatitis A vaccine (HepA)] |
| Q78546087 | [Approaches to development of hepatitis A vaccine and unresolved issues] |
| Q73493526 | [Characteristics of "Avaxim" hepatitis A vaccine produced by the firm "Pasteur Merrier" (results of field clinical trials)] |
| Q73493769 | [Comparative study of the reactivity, safety and immunogenicity of "Havrix" inactivated hepatitis A vaccine] |
| Q82529240 | [Comparison of antibody persistence between live attenuated and inactivated hepatitis A vaccines] |
| Q77512150 | [Comparison of immunology effects between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine] |
| Q73464836 | [Cost-benefit analysis for hepatitis A vaccine] |
| Q54476544 | [Effective inactivatian test of inactivated hepatitis A vaccine using integrated cell culture/strand-specific reverse transcriptase-polymerase chain reaction]. |
| Q78546091 | [Efficacy of immune serum globulin and hepatitis A vaccine with special reference to anti-HA antibody titers] |
| Q77677231 | [Epidemiological effects of live attenuated hepatitis A vaccine (H(2)-strain): results of A 10-year observation] |
| Q64126894 | [Evaluation on the role of hepatitis A vaccine in the prevention and control of hepatitis A in Tianjin city] |
| Q77735833 | [Experience in studying antigenic activity of inactivated hepatitis A vaccine] |
| Q73250584 | [Full effectiveness confirmed in more than 100,000 blood tests. Hepatitis A vaccine available again] |
| Q77511818 | [Further survey on efficacy of attenuated live hepatitis A vaccines] |
| Q71096509 | [Hepatitis A vaccine dosing] |
| Q72133894 | [Hepatitis A vaccine is available] |
| Q77512646 | [Horizontal transmission of live attenuated hepatitis A vaccine virus] |
| Q74498866 | [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)] |
| Q74101739 | [Immunogenicity and efficacy trials of live attenuated hepatitis A vaccines] |
| Q64133388 | [Immunogenicity and safety of three consecutive lots on an inactivated hepatitis A vaccine: a double-blind, immunogenicity and safety of three consecutive lots on a inactivated hepatitis A vaccine:a double-blind, randomized and controlled trial in c |
| Q72839183 | [Immunogenicity and stability of an aluminum-free liposomal hepatitis A vaccine (Epaxal Berna)] |
| Q74102073 | [Indications and prescription of hepatitis A vaccine in Spain. Report of the Spain Association for the Study of the Liver] |
| Q77537808 | [Indications and prescription of hepatitis A vaccine in Spain. Report of the Spanish Association for the Study of the Liver] |
| Q83168287 | [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years' follow up] |
| Q70470463 | [Observation of live, attenuated hepatitis A vaccines in humans] |
| Q71135978 | [Optimization of preparation conditions of an inactivated hepatitis A vaccine and its characteristics] |
| Q77676873 | [Primary study on immunologic effect of live attenuated hepatitis A vaccine (H2 strain) after booster dose] |
| Q57107220 | [Protective efficacy of H2 strain live attenuated hepatitis A vaccines in an outbreak of hepatitis A] |
| Q77532840 | [Recommendations for the use of the hepatitis A vaccine in day care centers. Committee on Vaccines of the Spanish Pediatric Society and Spanish Association for the Study of the Liver] |
| Q64131699 | [Research on the safety and immunogenicity of the domestic lyophilized live attenuated hepatitis A vaccine] |
| Q78034720 | [Safety and immunogenicity of a new inactivated hepatitis A vaccine] |
| Q54004871 | [Studies on re-immunization with live attenuated hepatitis A vaccine] |
| Q77512284 | [Studies on vaccination schedule of inactivated hepatitis A vaccine] |
| Q64133414 | [Study on the immunogenicity and safety of 2 kinds of inactivated hepatitis A vaccine vaccinated in 1-3 years old children] |
| Q92351582 | [The challenges of hepatitis A vaccine] |
| Q82662251 | [The immunological effects of three doses of a live attenuated hepatitis A vaccine (H2 strain) in 8 years] |
| Q77676981 | [The investigation on the safety and immunogenicity of inactived hepatitis A vaccine AVAXIM] |
| Q75196360 | [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children] |
| Q69824937 | [Trends in research in developing new type of vaccines--aiming at efficacy and safety. Viral hepatitis A vaccine] |
| Q51088648 | large-scale serologic testing program to assess the immunogenicity of inactivated hepatitis a vaccine (VAQTA) in prefilled syringes following product recall in Germany. |
| Q17066597 | Twinrix | subclass of | P279 |
| Q37155 | World Health Organization Model List of Essential Medicines | has part(s) | P527 |
Search more.